These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
554 related articles for article (PubMed ID: 3539322)
41. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines. Aida T; Bodell WJ Cancer Res; 1987 Mar; 47(5):1361-6. PubMed ID: 3469016 [TBL] [Abstract][Full Text] [Related]
42. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines. Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873 [TBL] [Abstract][Full Text] [Related]
43. Characterization of B16 melanoma cells resistant to the CC-1065 analogue U-71,184. Moy BC; Petzold GL; Badiner GJ; Kelly RC; Aristoff PA; Adams EG; Li LH; Bhuyan BK Cancer Res; 1990 Apr; 50(8):2485-92. PubMed ID: 2317831 [TBL] [Abstract][Full Text] [Related]
44. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Ekblad L; Kjellström J; Johnsson A Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208 [TBL] [Abstract][Full Text] [Related]
45. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657 [TBL] [Abstract][Full Text] [Related]
46. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096 [TBL] [Abstract][Full Text] [Related]
47. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Stordal BK; Davey MW; Davey RA Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310 [TBL] [Abstract][Full Text] [Related]
48. [Drug resistant mechanisms of platinum derivatives in a human cisplatin resistant ovarian cancer cell line]. Nishiya I; Yoshizumi N; Fujiwara J; Kagabu T Gan To Kagaku Ryoho; 1988 Oct; 15(10):2871-81. PubMed ID: 3178236 [TBL] [Abstract][Full Text] [Related]
49. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models. Deqnah N; Yu JQ; Beale P; Fisher K; Huq F Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298 [TBL] [Abstract][Full Text] [Related]
50. [Reduced cisplatin-uptake by cisplatin-resistant human ovarian cancer cells]. Kikuchi Y; Iwano I; Miyauchi M Gan To Kagaku Ryoho; 1988 Oct; 15(10):2895-8. PubMed ID: 3178239 [TBL] [Abstract][Full Text] [Related]
51. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539 [TBL] [Abstract][Full Text] [Related]
52. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Knox RJ; Friedlos F; Lydall DA; Roberts JJ Cancer Res; 1986 Apr; 46(4 Pt 2):1972-9. PubMed ID: 3512077 [TBL] [Abstract][Full Text] [Related]
53. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Kido Y; Khokhar AR; al-Baker S; Siddik ZH Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629 [TBL] [Abstract][Full Text] [Related]
54. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Kelland LR; Murrer BA; Abel G; Giandomenico CM; Mistry P; Harrap KR Cancer Res; 1992 Feb; 52(4):822-8. PubMed ID: 1737343 [TBL] [Abstract][Full Text] [Related]
55. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models. Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135 [TBL] [Abstract][Full Text] [Related]
56. Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line. Saburi Y; Nakagawa M; Ono M; Sakai M; Muramatsu M; Kohno K; Kuwano M Cancer Res; 1989 Dec; 49(24 Pt 1):7020-5. PubMed ID: 2479474 [TBL] [Abstract][Full Text] [Related]
57. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers. Monk BJ; Alberts DS; Burger RA; Fanta PT; Hallum AV; Hatch KD; Salmon SE Gynecol Oncol; 1998 Nov; 71(2):308-12. PubMed ID: 9826477 [TBL] [Abstract][Full Text] [Related]
58. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. Teicher BA; Herman TS; Holden SA; Epelbaum R; Liu SD; Frei E Cancer Res; 1991 Feb; 51(3):780-4. PubMed ID: 1988117 [TBL] [Abstract][Full Text] [Related]
59. In vitro studies on the mechanisms of oxaliplatin resistance. Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458 [TBL] [Abstract][Full Text] [Related]
60. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Lai SL; Hwang J; Perng RP; Whang-Peng J Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]